Everything below concerns Nucleotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
2010: Marcia McNutt became the first female director of the United States Geological Survey. 2011: Kazakhstani neuroscience student and computer hacker Alexandra Elbakyan launched Sci-Hub, a website that provides users with pirated copies of scholarly scientific papers. Within five years, Sci-Hub grew to contain 60 million papers and recorded over 42 million annual downloads by users. Elbakyan was finally sued by major academic publishing company Elsevier, and Sci-Hub was subsequently taken down, but it reappeared under different domain names. 2011: Taiwanese-American astrophysicist Chung-Pei Ma led a team of scientists in discovering two of the largest black holes ever observed. 2012: Israeli-American computer scientist and cryptographer Shafi Goldwasser won the Turing award for her contributions to cryptography and complexity theory. 2013: Canadian-British genetic specialist Turi King identified the 500-year-old skeletal remains of King Richard III. 2013: Kenyan ichthyologist Dorothy Wanja Nyingi published the first guide to freshwater fish species of Kenya. 2013: Canadian teenagers Miranda Wang and Jeanny Yao jointly identify a bacteria in British Columbia's Fraser River that breaks down phthalates. 2014: Norwegian psychologist and neuroscientist May-Britt Moser received the Nobel Prize in Physiology or Medicine, shared with Edvard Moser and John O'Keefe, "for their discoveries of cells that constitute a positioning system in the brain".
16 November – The SNP's National Executive Committee proposes cutting the number of staff at its headquarters from 26 to 16. Ruth Maguire, MSP for Cunninghame South, announces she will not seek re-election at the 2026 Scottish Parliament election because she is to undergo treatment for cancer. 17 November – At 12pm, Tesco opens its branch in Stornaway, Isle of Lewis for the first time on a Sunday, the Western Isles being the only place in the UK where the majority of shops remain closed on a Sunday. 19 November – Scottish Labour leader Anas Sarwar says his party will expand the eligibility for winter fuel payments in Scotland if they win the 2026 Scottish Parliament election. Eric Trump, the son of Donald Trump, confirms the US President-elect will visit Scotland in 2025 to open a new golf course. The Scottish Government is reported to be preparing to reduce the minimum term served by prisoners given short sentences, which could lead to the early release of between 260 and 390 prisoners in February 2025. 20 November – The Children and Young People's Commissioner Scotland launches an investigation into Police Scotland's use of force against children. 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. Traditional Scottish singer Iona Fyfe is named as the new Rector of the University of Aberdeen, succeeding Martina Chukwuma–Ezike, and will take up the post on 1 January 2025.
=== Contraindications === Known or suspected mechanical GI obstruction. Known hypersensitivity to lubiprostone or any ingredient in the formulation. The effects on pregnancy have not been studied in humans, but testing in guinea pigs resulted in fetal loss. Lubiprostone is contraindicated in people exhibiting chronic diarrhea, bowel obstruction, or diarrhea-predominant irritable bowel syndrome.
Protein therapeutics are proteins used as experimental or approved therapies for disease states. They include "monoclonal antibodies (mAbs), peptide hormones, growth factors, plasma proteins, enzymes, and hemolytic factors" While proteins can be more specific and flexible in their mechanism of action compared to small-molecule drugs, duration of action and drug delivery can be a challenge.
== Prognosis == Mild and moderate cerebral hypoxia may result in seizures and long-term memory impairment. The outcome of severe cerebral hypoxia will depend on the success of damage control, the amount of brain tissue deprived of oxygen, and the speed with which oxygen is restored. If cerebral hypoxia is localized to a specific part of the brain, brain damage will be localized to that region. A general consequence may be epilepsy. The long-term effects will depend on the purpose of that portion of the brain. Damage to the Broca's area and the Wernicke's area of the brain (left side) typically causes problems with speech and language. Damage to the right side of the brain may interfere with the ability to express emotions or interpret what one sees. Damage on either side can cause paralysis of the opposite side of the body. The effects of certain kinds of severe generalized hypoxias may take time to develop. For example, the long-term effects of serious carbon monoxide poisoning usually may take several weeks to appear. Recent research suggests this may be due to an autoimmune response caused by carbon monoxide-induced changes in the myelin sheath surrounding neurons. If hypoxia results in coma, the length of unconsciousness is often indicative of long-term damage. In some cases coma can allow the brain to heal and regenerate, but, in general, the longer a coma, the greater the likelihood that the person will remain in a vegetative state until death. Even if the patient wakes up, brain damage is likely to be significant enough to prevent a return to normal functioning.
Sources: en.wikipedia.org
A major part of EU law, and most of the EU's budget, concerns public regulation of enterprise and public services. A basic norm of the Treaty on the Functioning of the EU, in article 345, is that the "Treaties shall in no way prejudice the rules in Member States governing the system of property ownership", meaning the EU remains neutral between private or public ownership, but that it can require common standards. In the cases of education and health, member states generally organise public services and the EU requires free movement. There is a unified European Central Bank that funds private banks, and adopts a common monetary policy for price stability, employment and sustainability. The EU's policies on energy, agriculture and forestry, transport and buildings are crucial to end climate damage and shift completely to clean energy that does not heat the planet. Among these, 33% of the entire EU budget is spent on agricultural subsidies to farm corporations and owners. The EU also has an increasing number of policies to raise standards for communications, the internet, data protection, and online media. It has limited involvement in the military and security, but a Common Foreign and Security Policy.
==== Energy ==== The Lula government inaugurated, on 22 March, the first hybrid Renewable energy park in the country authorized by the National Electric Energy Agency (Aneel): the "Neo-energy Renewable Complex – Fountain Wind Farm", which consists of renewable Wind power and solar energy, located in Santa Luzia, Paraíba. In a meeting with the Minister of Mines and Energy, Alexandre Silveira, Lula showed support for the use of electricity derived from renewable sources, in particular for reducing the cost of the service, especially for the poor; goals were also discussed to place Brazil in a "leading global position in the generation of clean energy", in addition to encouraging more sustainable public transport.
=== Parkinson's disease === Mesocarb, has been under development for the treatment of Parkinson's disease since 2016. As of February 2023, it is in phase 1 clinical trials for this indication. However, no recent development has been reported. Mesocarb's active enantiomer armesocarb is also under development.
All uranium fluorides are created using uranium tetrafluoride (UF4); UF4 itself is prepared by hydrofluorination of uranium dioxide. Reduction of UF4 with hydrogen at 1000 °C produces uranium trifluoride (UF3). Under the right conditions of temperature and pressure, the reaction of solid UF4 with gaseous uranium hexafluoride (UF6) can form the intermediate fluorides of U2F9, U4F17, and UF5. At room temperatures, UF6 has a high vapor pressure, making it useful in the gaseous diffusion process to separate the rare uranium-235 from the common uranium-238 isotope. This compound can be prepared from uranium dioxide and uranium hydride by the following process:
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.